Project Grant R01CA290875
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$550K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94104, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding for research to develop a novel radioimmunotherapy (RIT) targeting the active conformation of integrin beta-2 (AITGB2) as a potential treatment for acute myeloid leukemia (AML). The award of $678,101 to the University of California, San Francisco will support a rigorous preclinical evaluation of the 7065 antibody-based RIT, including assessments of its efficacy, toxicity, and...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $676,006 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at early identification of resistance to immunotherapy for cancer treatment. The key products and services to be delivered under this 5-year award include: Developing and testing non-invasive imaging strategies, such as PET scans and implantable fluorescence sensors,...
This National Cancer Institute (NCI) Project Grant award under CFDA 93.396 - Cancer Biology Research provides $552,874 in funding to The Regents of the University of California, San Francisco (UCSF) from August 1, 2024 to July 31, 2029. The project aims to dissect the cellular and molecular pathways by which the A20 protein regulates anti-tumor immunity. Specifically, the research will focus on understanding how A20, a potent regulator of immune homeostasis, restrains both acute and anamnestic...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides funding of $695,916 to The Regents of the University of California, San Francisco (UCSF) to evaluate and optimize novel inhibitors of the NSMASE2 enzyme for enhancing the effectiveness of immune checkpoint inhibitors in cancer treatment. The project aims to synthesize and test PDDC analogs to improve the potency, solubility, and pharmacokinetics of NSMASE2 inhibitors. Promising...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports fundamental research aimed at understanding the biological mechanisms underlying acute myeloid leukemia (AML) development and progression. The $487,973 award to The Leland Stanford Junior University will fund a 5-year project investigating the role of pre-leukemic hematopoietic stem cells (pHSCs) in AML pathogenesis. The research will explore the clonal evolution, kinetics, and cell...
This Project Grant award of $458,698.00 was provided by the National Cancer Institute (NCI) under the federal Cancer Biology Research program (CFDA 93.396). The award, effective March 10, 2025 through February 28, 2030, supports research to identify novel genes and mechanisms underlying therapy resistance and relapse in acute myeloid leukemia (AML). The research aims to functionally validate candidate genes from prior single-cell RNA sequencing and CRISPR screens in order to better understand...
The University of California, Davis was awarded a $615,399 Project Grant by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to develop a transformable nanoparticle (TNP) platform capable of transforming into nanofibrillar networks that can effectively deliver immunomodulatory peptides, small molecules, and proteins to the tumor microenvironment. This 5-year research project aims to optimize the TNP/TCTS therapeutic platform for on-demand modulation of the tumor...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $439,644 to The Leland Stanford Junior University to conduct functional studies on human acute myeloid leukemia (AML) stem cells. The key objectives are to: 1) Investigate the relationship between specific genetic mutations and AML stem cell frequency, disease initiation, and disease maintenance by correcting mutations in primary AML cells and AML-induced pluripotent stem cells (iPSCs);...
This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,292,000.00 to the University of California, San Francisco (UCSF) to conduct in vivo mechanistic characterization of the angiogenic immune checkpoint in liver cancer. The research aims to transform healthcare for Service Members and the American public through innovative and impactful biomedical investigations. The 4-year research project will involve...
This $1,398,552 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports Avantgen Inc., a San Diego-based biotechnology company, in conducting preliminary IND-enabling studies for a novel antibody therapy targeting the Jagged-1 pathway in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The key products and services to be delivered under this grant include cell line development, early chemistry and manufacturing controls (CMC)...